Navigation Links
Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
Date:3/4/2013

requent adverse events (AEs) in STARTVerso™ 4 were nausea (37%), fatigue (33%), diarrhea (27%), headache (23%), and weakness (22%). Serious AEs were reported in 32 patients (10%), including three deaths. To date, 18 patients have discontinued study participation due to AEs. The safety results of this study were comparable to those observed in HCV mono-infected treatment-naive patients in prior faldaprevir clinical studies. No patient on ART experienced a loss of HIV viral suppression during the study period.

In a separate oral presentation at CROI, investigators described the results from three open-label Phase 1 studies in healthy volunteers that evaluated the drug-drug interactions of faldaprevir with the common HIV medications darunavir/ritonavir, efavirenz, or tenofovir. In each of these studies, there was no clinically relevant effect of faldaprevir on the pharmacokinetics of any of the HIV medications studied. However, the respective effects of darunavir/ritonavir and efavirenz on faldaprevir informed the study design of STARTVerso™ 4. Patients already taking darunavir/ritonavir or efavirenz were enrolled into the 120mg and 240mg faldaprevir groups in STARTVerso™ 4, respectively.

These drug-drug interaction findings are part of a comprehensive program to evaluate potential drug interactions of faldaprevir with other medications commonly taken by the diverse patient populations infected with HCV. Most AEs in the drug-drug interaction studies were mild or moderate and all were resolved by the end of the trials. Four healthy volunteers discontinued trial participation due to AEs, including mild or moderate rash, mild elevation in hepatic enzyme levels, or moderate myalgia.

"The interim virologic response rates from STARTVerso™ 4 in HCV/HIV co-infected patients, combined with the drug-drug interaction results of faldaprevir with common HIV medications, are encouraging as we continue toward our goal of developing new HCV
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... KALAMAZOO, Mich. , June 29, 2015 /PRNewswire/ ... Association and American Stroke Association give hope for ... patients who experience an acute ischemic stroke each ... of the key products used in the clinical ... The new AHA/ASA guidelines strongly recommend endovascular ...
(Date:6/29/2015)... , June 29, 2015 ... positive preliminary results from its BVX-006 Phase II clinical ... vaccine. In this trial, M-001 was injected intramuscularly to ... by an administration of the 2014/15 season trivalent influenza ... be safe and well tolerated and induced humoral immune ...
(Date:6/29/2015)... Calif. , June 29, 2015  Isis Pharmaceuticals, ... has been added to the Russell 1000 Index, effective ... performance of the large-cap segment of the U.S. equity ... Index and includes approximately 1000 of the largest securities ... current index membership. "We are pleased to ...
Breaking Medicine Technology:New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 2New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 3BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3
... JERUSALEM, Oct. 13, 2011 IDenta Corp. (OTC: IDTA) CEO ... Shoham stated, "We are succeeding in making sales in many ... products. We have received an order for 2000 ... http://www.gksolutions.com.au/ In the past several ...
... Association for Homecare urges the Joint Select Committee on ... cuts that will restrict access to home medical ... Over the years, homecare has broadened health care access ... the health care system by keeping seniors and people ...
Cached Medicine Technology:International Drug & Explosives Detection Company IDenta Corp. Receives Order From Australia 2American Association for Homecare Calls on Joint Deficit Committee in Congress to Preserve Homecare Access for Millions of Americans 2
(Date:6/29/2015)... ... June 29, 2015 , ... ... contractors, nonprofits, independent schools, and other growing businesses across the United States, has ... Value Added Resellers for the fifth consecutive year. , Based on company revenue ...
(Date:6/29/2015)... (PRWEB) , ... June 29, 2015 , ... ... have developed a new approach to build nearly complete genomes by combining high-throughput ... of genomic variation, critically important for their association with human disease, but previously ...
(Date:6/29/2015)... ... June 29, 2015 , ... San Fernando Valley skin doctor ... sagging skin. Ulthera is a special treatment that offers a way to firm sagging ... gently stimulate collagen production. Ulthera is highly targeted and precise to help reduce treatment ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... and Chemical Technology of The Hong Kong Polytechnic University (PolyU) has developed a ... Authentication of edible oils has been a long-term issue in food safety, and ...
(Date:6/29/2015)... ... June 29, 2015 , ... Minneapolis Saint Paul ... Cities area, provides money-saving tactics during a season of increased water and air ... water conservation and other economical practices. , According to the U.S. Department ...
Breaking Medicine News(10 mins):Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 2Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 4Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 2Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 3Health News:PolyU develops a new method for rapid authentication of edible oils and screening of gutter oils 2Health News:Save Energy: MSP Plumbing, Heating & Air Endorses Efficiency 2Health News:Save Energy: MSP Plumbing, Heating & Air Endorses Efficiency 3
... reservations on one side and on the other side increasing ... not suffer is the UPA Government’s please-all formula//. ... 27 per cent of the seats in Central educational institutions ... 2007. Simultaneously, it has been decided to increase the number ...
... A group of autoimmune diseases, named Juvenile rheumatoid ... which inversely affect health-related quality of life// , ... adults – study finds. But nothing regarding children ... Research journal published a study in the June ...
... entrance test tomorrow to join the MBBS course at ... Education and Research (JIPMER) here. // ,These ... in Pondicherry, New Delhi, Chennai, Hyderabad, Kolkata and Thiruvananthapuram ... the Dean the institute Dr K S Reddy said ...
... Indian Medical Association today said that private doctors have announced ... for OBCs // , and have decided to close their ... Dental Association, Rajkot, have also extended its support to anti-quota ... release here., ,At least 70 medical students and junior ...
... A study by Florida State University researchers said, ‘Self-critical adult ... they are grown up in a verbally// abused environment in ... times more likely to have symptoms of depression and anxiety ... on 5,614 people aged between 15 and 54, conducted by ...
... planning to bifurcate the Health and Family Welfare Department ... This step is thought to allow for streamlined health ... R Ashok said that the step was being taken ... system. Initially the government will ask 23 doctors who ...
Cached Medicine News:Health News:The Government’s Balancing Act on Reservatio 2Health News:The Government’s Balancing Act on Reservatio 3Health News:Socioeconomic Status Plays A Role In Juvenile Rheumatoid Arthritis 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: